The National Pregnancy Registry for Atypical Antipsychotics was created with a view to consider the security of atypical antipsychotic medicines taken by ladies throughout being pregnant. Since its inception, we now have enrolled over 3000 ladies within the registry, and we now have been capable of publish information on the reproductive security of aripiprazole (Abilify), olanzapine (Zyprexa) and quetiapine (Seroquel). Now we now have some preliminary information on using lurasidone (Latuda) throughout being pregnant.
The Nationwide Being pregnant Registry for Atypical Antipsychotics is a potential pharmacovigilance program through which pregnant ladies between the ages of 18 and 45 are enrolled and interviewed throughout being pregnant. Medical data are reviewed to substantiate the presence or absence of main malformations.
Of the two,293 ladies enrolled on the time of research, there have been 134 within the lurasidone publicity group, 264 within the quetiapine publicity group, and 886 controls. The chance of main malformations was 2.19% within the lurasidone group, 1.85% within the quetiapine group, and 1.77% within the controls. Odds ratios evaluating lurasidone and quetiapine with controls had been 1.24 (95% confidence interval [CI] = 0.36-4.32) and 1.04 (95% CI = 0.38-2.85), respectively. No particular patterns of malformations had been noticed in infants uncovered to the medicines.
Reassuring Information However Extra Information on Lurasidone is Wanted
The newer atypical or second-generation antipsychotic brokers are used to deal with a spectrum of psychiatric problems, together with psychotic problems, bipolar dysfunction, main melancholy, PTSD and different anxiousness problems. Our information on the reproductive security of those newer atypical brokers is rising.
This research gives reassuring information concerning the security of prenatal publicity to lurasidone and quetiapine in a pattern of well-characterized members adopted prospectively and is per earlier research assessing infants uncovered to this class of medicines. Based mostly on the findings of this research, it seems that lurasidone and quetiapine don’t look like main teratogens. No research to this point have demonstrated a rise in threat of malformations in youngsters uncovered to atypical antipsychotics.
Whereas the preliminary information from this research is reassuring, bigger numbers of members are wanted to supply extra full information concerning the reproductive security of atypical antipsychotics as a category of medicines. These findings, taken along with other studies, counsel that prenatal publicity to atypical antipsychotics doesn’t seem to considerably improve the danger for congenital malformations, though we now have only a few documented exposures to a few of the latest atypicals, together with lurasidone (Latuda), iloperidone (Fanapt), brexpiprazole (Rexulti), and cariprazine (Vraylar).
The National Pregnancy Registry for Atypical Antipsychotics continues to recruit pregnant ladies taking atypical antipsychotic medicines. CALL TOLL-FREE to study extra 1-866-961-2388 or fill out this Patient Interest Form to be contacted by our analysis coordinator. All info is stored strictly confidential. Participation consists of three telephone interviews.
Ruta Nonacs, MD PhD
Cohen LS, Church TR, Freeman MP, Gaccione P, Caplin PS, Kobylski LA, Arakelian M, Rossa ET, Chitayat D, Hernández-Díaz S, Viguera AC. Reproductive Safety of Lurasidone and Quetiapine: Update from the National Pregnancy Registry for Psychiatric Medications. J Womens Well being (Larchmt). 2023 Jan 30.
